On September 14, GENSCRIPT BIO fell 3.15% in regular trading, trading at HK$31.12 per share, with turnover of HK$58.10 million. The decline comes as the company's discounted share placement approaches its expected settlement date of September 15.

GENSCRIPT BIO previously announced a placement of 77.126 million new shares at HK$30.50 each, representing a discount of approximately 4.7% to the prior closing price of HK$32.00. The placement, arranged by Citigroup and J.P. Morgan as placing agents, is expected to generate net proceeds of approximately HK$2.327 billion. Following completion, major shareholder GenScript Corporation's stake will be diluted from 36.32% to 35.09%. Net proceeds are earmarked for expanding capacity and infrastructure for the company's AI-driven drug discovery platform, as well as research, development, and general corporate purposes.

With the settlement date imminent, the short-term dilution effect and the placement price sitting below the current market price are exerting downward gravitational pressure on shares. The stock is now trading close to the HK$30.50 placement price level.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)